NASDAQ:DNLI

Denali Therapeutics Stock Forecast, Price & News

$49.86
-2.97 (-5.62 %)
(As of 09/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$49.02
$52.68
50-Day Range
$48.48
$69.53
52-Week Range
$33.68
$93.94
Volume822,459 shs
Average Volume582,767 shs
Market Capitalization$6.06 billion
P/E Ratio171.93
Dividend YieldN/A
Beta1.88
30 days | 90 days | 365 days | Advanced Chart
Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Denali Therapeutics logo

About Denali Therapeutics

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.24 out of 5 stars

Medical Sector

312th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

44th out of 193 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

Is Denali Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Denali Therapeutics?

Wall Street analysts have given Denali Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Denali Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Denali Therapeutics
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.14. The company had revenue of $22.94 million for the quarter, compared to the consensus estimate of $27.92 million. Denali Therapeutics had a net margin of 15.66% and a trailing twelve-month return on equity of 5.31%. The company's revenue was up 292.3% compared to the same quarter last year.
View Denali Therapeutics' earnings history
.

How has Denali Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DNLI shares have increased by 195.4% and is now trading at $49.86.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for DNLI?

10 analysts have issued 12 month price objectives for Denali Therapeutics' stock. Their forecasts range from $50.00 to $105.00. On average, they expect Denali Therapeutics' share price to reach $81.63 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price.
View analysts' price targets for Denali Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Denali Therapeutics' key competitors?

What other stocks do shareholders of Denali Therapeutics own?

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (12.50%), Vanguard Group Inc. (6.28%), BlackRock Inc. (5.78%), Price T Rowe Associates Inc. MD (4.03%), FMR LLC (2.19%) and State Street Corp (1.91%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics
.

Which major investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Vanguard Group Inc., Marshall Wace North America L.P., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Mark Asset Management LP, Cubist Systematic Strategies LLC, and Man Group plc. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics
or view top insider-selling stocks.

Which major investors are buying Denali Therapeutics stock?

DNLI stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Invesco Ltd., State Street Corp, Geode Capital Management LLC, and Northern Trust Corp.
View insider buying and selling activity for Denali Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $49.86.

How much money does Denali Therapeutics make?

Denali Therapeutics has a market capitalization of $6.06 billion and generates $335.66 million in revenue each year. The company earns $71.14 million in net income (profit) each year or $0.63 on an earnings per share basis.

How many employees does Denali Therapeutics have?

Denali Therapeutics employs 291 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

Where are Denali Therapeutics' headquarters?

Denali Therapeutics is headquartered at 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (615) 866-8548 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.